UBS Maintains Neutral on Medpace Holdings, Raises Price Target to $700
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
UBS analyst Kevin Caliendo maintains Medpace Holdings (NASDAQ:MEDP) with a Neutral and raises the price target from $673 to $700.
UBS analyst Kevin Caliendo maintains Medpace Holdings (NASDAQ:MEDP) with a Neutral and raises the price target from $673 to $700.